Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

Trial Identifier: D0817R00011
Sponsor: AstraZeneca
NCTID:: NCT04560452
Start Date: June 2021
Primary Completion Date: April 2025
Study Completion Date: April 2025
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China, Beijing Beijing, China, 100700
China, Beijing Beijing, China, 100730
China, Beijing Beijing, China, 100034
China, Fujian Xiamen, Fujian, China, 361003
China, Guangdong Guangzhou, Guangdong, China, 510120
China, Guangdong Guangzhou, Guangdong, China, 510630
China, Guangdong Gugngzhou, Guangdong, China, 511400
China, Guangdong Shantou, Guangdong, China, 515041
China, Guangdong Shenzhen, Guangdong, China, 518117
China, Guangdong Shenzhen, Guangdong, China, 518020
China, Guizhou Guiyang, Guizhou, China, 550004
China, He nan Zhengzhou, He nan, China, 450003
China, He nan Zhengzhou, He nan, China, 450008
China, He nan Zhengzhou, He nan, China, 450052
China, Hebei Langfang, Hebei, China, 65700
China, Hebei Shijiazhuang, Hebei, China, 50019
China, Heilongjiang Harbin, Heilongjiang, China, 150081
China, Jiangsu Nanjing, Jiangsu, China, 210029
China, Jiangsu Nanjing, Jiangsu, China, 210009
China, Jiangsu Suzhou, Jiangsu, China, 215600
China, Liaoning Shenyang, Liaoning, China, 110004
China, Liaoning Shenyang, Liaoning, China, 110122
China, Shandong Ji nan, Shandong, China, 250117
China, Shanghai shanghai, Shanghai, China, 200092
China, Shanghai shanghai, Shanghai, China, 200032
China, Shanghai Shanghai, China, 200025
China, Sichuan Chengdu, Sichuan, China, 610041
China, Tianjin Tianjin, China, 300050
China, Yunan Kunming, Yunan, China, 650118
China, Zhejiang Hangzhou, Zhejiang, China, 310006
China, Zhejiang Hangzhou, Zhejiang, China, 310009